Sectors

Strong engagement, open dialogue, and a shared focus on the future. Last week, ICON CEO, Barry Balfe, connected with teams in our São Paulo and Mexico City offices, hosting a series of highly engaged town halls. The vis...

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...

Recent biosimilar regulatory changes have led to a perceived lower barrier to entry for developers of all sizes, introducing heightened competition. Read the whitepaper to learn how biosimilar developers can prepare fo...

In 2025, the EMA and FDA each released regulatory guidance that impacts the development and approval processes for biosimilars, such as by waiving the need for comparative clinical efficacy studies in some circumstances....

ICON is excited to sponsor RAPS Euro Convergence 2026, taking place 5–8 May in Lisbon. Visit us at booth \#21 to meet our team and discuss how ICON combines expertise and experience with the latest in productivity tool...

Clinical research is evolving at pace and so is the role of the Clinical Research Associate. From increased use of technology and data, to more strategic site partnerships, today’s CRA plays a critical role in deliverin...

New methods for gathering long-term data are emerging through the use of RWD and tokenisation, providing new options for vaccine follow-up strategies. Find out what developers should ask to determine if these new strateg...

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP-1-Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

ICON is once again sponsoring and presenting at #OCTEU26 on 6–7 May in Barcelona, which focuses on the evolving needs of the biotechnology sector within clinical research. The meeting highlights scientific innovation alo...

Frequentist and Bayesian frameworks in NMA Different analytical paradigms offer different strengths. The whitepaper sets out the contrasting roles of frequentist regression based models and Bayesian hierarchical models,...

ICON is proud to mark World Parkinson’s Day by highlighting the vital role of clinical research in advancing care for people living with Parkinson’s. Over the past 5 years, we have conducted 93 Neurodegeneration studie...

Selecting the right pediatric HRQoL instrument is no longer optional. It’s a regulatory expectation. Our latest blog breaks down a six criterion framework to guide sponsors in making defensible, patient focused choices, ...